Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide vs Sitagliptin Add-On to Insulin Glargine in T2DM
NCT02200991Phase 4Completed
- Sponsor
- Sanofi
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Postprandial Plasma Glucose Area Under the Curve at 29 days. Started Aug 2014; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02200991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200991.